NCT07201376 2026-02-06
PPIX
Dartmouth-Hitchcock Medical Center
Recruiting
Clinical Trials
18 trialsNCT01803477 2025-02-24
Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm
LEO Pharma
Phase 1/2 Completed
NCT05387525 2025-02-11
AKtive
Almirall, S.A.
Phase 4 Active not recruiting
NCT06745999 2024-12-24
Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face
Psoriasis Treatment Center of Central New Jersey
Phase 4 Unknown
NCT06577311 2024-08-29
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
The Center for Clinical and Cosmetic Research
Phase 2 Recruiting
NCT06409195 2024-05-10
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers
DermBiont, Inc.
Phase 2 Recruiting
NCT03546166 2023-07-21
PICABAS
Centre Hospitalier Universitaire de Nice
Phase 2 Completed
NCT03380026 2021-11-24
MIDAS
Rochester Skin Lymphoma Medical Group, PLLC
Phase 2 Completed
NCT03826550 2019-02-01
Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis
Encube Ethicals Pvt. Ltd.
Phase 3 Completed
NCT03508856 2018-04-26
Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin
Skin Laser & Surgery Specialists
Phase NA Completed
NCT00850681 2015-09-09
A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
Peplin
Phase 1 Completed
NCT00850811 2015-09-09
A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
Peplin
Phase 1 Completed
NCT00742391 2015-03-06
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Peplin
Phase 3 Completed
NCT00852137 2015-03-06
A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
Peplin
Phase 2 Completed
NCT00915551 2015-03-06
A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
Peplin
Phase 3 Completed
NCT00942604 2015-03-06
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Peplin
Phase 3 Completed
NCT00322296 2013-04-16
Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis
Fox Chase Cancer Center
Phase 2 Terminated
NCT01214564 2011-01-25
Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis
Peplin
Phase 2 Completed